Vida Ventures News Today

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Proceeds support advancement of two next-generation precision oncology programs into clinical development within 12 monthsFinancing led by Goldman Sachs Alternatives with participation by Canaan Partners, Driehaus Capital Management, Invus, Digitalis Ventures, Blue Owl Capital, and existing investorsSAN DI...

Alterome Therapeutics, a biopharmaceutical company, has closed a $132m Series B financing round.

Cell therapies were first validated in cancer, but Kyverna Therapeutics aims to show they’re safe enough for autoimmune diseases. The biotech plans to deploy its IPO cash across clinical trials in lupus nephritis, multiple sclerosis, systemic sclerosis, and myasthenia gravis.

Bringing Taiwan to the World and the World to Taiwan

(Bloomberg) -- Kyverna Therapeutics Inc. raised $319 million in a US initial public offering priced above a marketed range, as drug developers continue to receive a warm welcome from new investors.Most Read from BloombergCitadel Among Hedge Funds That Got Morgan Stanley’s Block-Trading LeaksTesla Asks Which Jobs Are Critical, Stoking Layoff FearsChina Replaces Top Markets Regulator as Xi Tries to End RoutUS Commercial Real Estate Contagion Is Now Moving to EuropeHaley Loses Nevada Primary...

A16z’s consumer AI bets will emphasize creative applications, improved workflows, and AI companionship.

Combined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic’s novel GPCR-targeted therapeutic proteins $130.7 million in private financing...

Sam Altman is a leading voice at Davos, which means he’s sounding off on everything from elections to energy. It also means he’s more watched than ever.

Life sciences veteran’s experience leading R&D organizations and bringing more than 25 products to market will support Volastra’s growing pipeline of treatments targeting chromosomally unstable cancersNEW YORK--(BUSINESS WIRE)--Volastra Therapeutics, a clinical-stage cancer biotechnology company, today announced the...